The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Karim Fizazi

Institut Gustave Roussy and University of Paris XI

39 Rue Camille Desmoulins




Name/email consistency: high



  • Institut Gustave Roussy and University of Paris XI, 39 Rue Camille Desmoulins, Villejuif, France. 2013
  • Institut Gustave Roussy, Villejuif, France. 1998 - 2012
  • Genito-Urinary Group of the French Federation of Cancer Centers, Paris, France. 2004
  • Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, USA. 2002
  • Institut Gustave Roussy, Villejuif, Centre Léon Bérard, Lyon, and Centre Val d'Aurelle, France. 2001
  • Institut Gustave-Roussy, Villejuif, and AstraZeneca Pharmaceuticals, Cergy, France. 2000


  1. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. Fizazi, K., Bosserman, L., Gao, G., Skacel, T., Markus, R. J. Urol. (2013) [Pubmed]
  2. A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. Fizazi, K., Lesaunier, F., Delva, R., Gravis, G., Rolland, F., Priou, F., Ferrero, J.M., Houedé, N., Mourey, L., Theodore, C., Krakowski, I., Berdah, J.F., Baciuchka, M., Laguerre, B., Fléchon, A., Ravaud, A., Cojean-Zelek, I., Oudard, S., Labourey, J.L., Lagrange, J.L., Chinet-Charrot, P., Linassier, C., Deplanque, G., Beuzeboc, P., Geneve, J., Davin, J.L., Tournay, E., Culine, S. Eur. J. Cancer (2012) [Pubmed]
  3. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., Jiang, Q., Tadros, S., Dansey, R., Goessl, C. Lancet (2011) [Pubmed]
  4. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. Fizazi, K., Beuzeboc, P., Lumbroso, J., Haddad, V., Massard, C., Gross-Goupil, M., Di Palma, M., Escudier, B., Theodore, C., Loriot, Y., Tournay, E., Bouzy, J., Laplanche, A. J. Clin. Oncol. (2009) [Pubmed]
  5. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. Fizazi, K., Bosserman, L., Gao, G., Skacel, T., Markus, R. J. Urol. (2009) [Pubmed]
  6. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Fizazi, K., Lipton, A., Mariette, X., Body, J.J., Rahim, Y., Gralow, J.R., Gao, G., Wu, L., Sohn, W., Jun, S. J. Clin. Oncol. (2009) [Pubmed]
  7. Specific endothelin-A receptor antagonism for the treatment of advanced prostate cancer. Fizazi, K., Miller, K. BJU Int. (2009) [Pubmed]
  8. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Fizazi, K., Oldenburg, J., Dunant, A., Chen, I., Salvioni, R., Hartmann, J.T., De Santis, M., Daugaard, G., Flechon, A., de Giorgi, U., Tjulandin, S., Schmoll, H.J., Bouzy, J., Fossa, S.D., Fromont, G. Ann. Oncol. (2008) [Pubmed]
  9. The role of Src in prostate cancer. Fizazi, K. Ann. Oncol. (2007) [Pubmed]
  10. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Fizazi, K., Le Maitre, A., Hudes, G., Berry, W.R., Kelly, W.K., Eymard, J.C., Logothetis, C.J., Pignon, J.P., Michiels, S. Lancet Oncol. (2007) [Pubmed]
  11. High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity. Fizazi, K., Morat, L., Chauveinc, L., Prapotnich, D., De Crevoisier, R., Escudier, B., Cathelineau, X., Rozet, F., Vallancien, G., Sabatier, L., Soria, J.C. Ann. Oncol. (2007) [Pubmed]
  12. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. Fizazi, K., Culine, S., Kramar, A., Amato, R.J., Bouzy, J., Chen, I., Droz, J.P., Logothetis, C.J. J. Clin. Oncol. (2004) [Pubmed]
  13. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Fizazi, K., Sikes, C.R., Kim, J., Yang, J., Martinez, L.A., Olive, M.C., Logothetis, C.J., Navone, N.M. Anticancer Res. (2004) [Pubmed]
  14. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. Fizazi, K., Doubre, H., Le Chevalier, T., Riviere, A., Viala, J., Daniel, C., Robert, L., Barthélemy, P., Fandi, A., Ruffié, P. J. Clin. Oncol. (2003) [Pubmed]
  15. A phase II study of irinotecan in patients with advanced renal cell carcinoma. Fizazi, K., Rolland, F., Chevreau, C., Droz, J.P., Mery-Mignard, D., Culine, S., Escudier, B. Cancer (2003) [Pubmed]
  16. A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial. Fizazi, K., Do, K.A., Wang, X., Finn, L., Logothetis, C.J., Amato, R.J. Ann. Oncol. (2002) [Pubmed]
  17. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Fizazi, K., Prow, D.M., Do, K.A., Wang, X., Finn, L., Kim, J., Daliani, D., Papandreou, C.N., Tu, S.M., Millikan, R.E., Pagliaro, L.C., Logothetis, C.J., Amato, R.J. Br. J. Cancer (2002) [Pubmed]
  18. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. Fizazi, K., Tjulandin, S., Salvioni, R., Germà-Lluch, J.R., Bouzy, J., Ragan, D., Bokemeyer, C., Gerl, A., Fléchon, A., de Bono, J.S., Stenning, S., Horwich, A., Pont, J., Albers, P., De Giorgi, U., Bower, M., Bulanov, A., Pizzocaro, G., Aparicio, J., Nichols, C.R., Théodore, C., Hartmann, J.T., Schmoll, H.J., Kaye, S.B., Culine, S., Droz, J.P., Mahé, C. J. Clin. Oncol. (2001) [Pubmed]
  19. Germ cell tumors in patients infected by the human immunodeficiency virus. Fizazi, K., Amato, R.J., Beuzeboc, P., Petit, N., Bouhour, D., Thiss, A., Rebischung, C., Chevreau, C., Logothetis, C.J., Droz, J.P. Cancer (2001) [Pubmed]
  20. Is òne cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms. Fizazi, K., Zelek, L. Ann. Oncol. (2000) [Pubmed]
  21. Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer. Fizazi, K., Ducreux, M., Ruffié, P., Bonnay, M., Daniel, C., Soria, J.C., Hill, C., Fandi, A., Poterre, M., Smith, M., Armand, J.P. J. Clin. Oncol. (2000) [Pubmed]
  22. Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma. Fizazi, K., Caliandro, R., Soulié, P., Fandi, A., Daniel, C., Bedin, A., Doubre, H., Viala, J., Rodier, J., Trandafir, L., Le Chevalier, T., Cvitkovic, E., Armand, J., Ruffié, P. Eur. J. Cancer (2000) [Pubmed]
  23. Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. Fizazi, K., Dohollou, N., Blay, J.Y., Guérin, S., Le Cesne, A., André, F., Pouillart, P., Tursz, T., Nguyen, B.B. J. Clin. Oncol. (1998) [Pubmed]
WikiGenes - Universities